Skip to main content
Top
Published in: Diabetologia 2/2009

01-02-2009 | Letter

Ramadan-focused education and awareness in type 2 diabetes

Authors: M. Hassanein, V. Bravis, E. Hui, D. Devendra

Published in: Diabetologia | Issue 2/2009

Login to get access

Excerpt

To the Editor: Millions of Muslims across the world fast with complete dedication during the month of Ramadan: this is one of the five main pillars of the Muslim faith. During this month, Muslims fast from dawn to dusk. However, as fasting is not meant to create excessive hardship for an individual, the Koran exempts many people from fasting, including anyone who is ill [1]. Consequently, both religious and medical advice is that generally people with diabetes should not fast, as their metabolic condition could be adversely affected [1, 2]. Of the 14 million Muslims living in Europe [3], the number with diabetes is not known. The majority of Muslim patients with diabetes are passionate about the Ramadan fast but are unaware of the possible complications of fasting, which include hyperglycaemia, hypoglycaemia, and increased risk of dehydration and thrombosis [2, 4]. The Epidemiology of Diabetes and Ramadan (EPIDIAR) study showed that in 13 non-European nations, 79% of Muslim patients with type 2 diabetes fasted for more than 15 days during Ramadan. The study also showed that there was a three- to fivefold increase in the incidence of severe hypoglycaemia during this fasting period [4]. …
Literature
1.
go back to reference The Holy Koran. Sûrah al-Baqarah 2:183–185 The Holy Koran. Sûrah al-Baqarah 2:183–185
3.
go back to reference Gan D (2003) Executive summary. In: Diabetes atlas, 2nd edn. International Diabetes Federation, Brussels Gan D (2003) Executive summary. In: Diabetes atlas, 2nd edn. International Diabetes Federation, Brussels
4.
go back to reference Salti I, Bénard E, Detournay B et al (2004) A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries. Results of the Epidemiology of Diabetes and Ramadan (EPIDIAR) study. Diabetes Care 27:2306–2311PubMedCrossRef Salti I, Bénard E, Detournay B et al (2004) A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries. Results of the Epidemiology of Diabetes and Ramadan (EPIDIAR) study. Diabetes Care 27:2306–2311PubMedCrossRef
5.
go back to reference Al-Arouj M, Bouguerra R, Buse J et al (2005) Recommendations for management of diabetes during Ramadan. Diabetes Care 28:2305–2311PubMedCrossRef Al-Arouj M, Bouguerra R, Buse J et al (2005) Recommendations for management of diabetes during Ramadan. Diabetes Care 28:2305–2311PubMedCrossRef
6.
go back to reference Bravis V, Hui E, Salih S et al (2008) European implications of the READ (Ramadan focused Education and Awareness in Diabetes) programme. Diabetologia 51(Suppl1 S454):A1114 (Abstract) Bravis V, Hui E, Salih S et al (2008) European implications of the READ (Ramadan focused Education and Awareness in Diabetes) programme. Diabetologia 51(Suppl1 S454):A1114 (Abstract)
Metadata
Title
Ramadan-focused education and awareness in type 2 diabetes
Authors
M. Hassanein
V. Bravis
E. Hui
D. Devendra
Publication date
01-02-2009
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 2/2009
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-008-1220-8

Other articles of this Issue 2/2009

Diabetologia 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine